Bellerophon Therapeutics Stock News

Northern Trust Corp lessened its position in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) by 51.6% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 36,555 shares of the biotechnology companys stock after selling 39,024 shares during the quarter. Northern Trust Corps holdings in Bellerophon Therapeutics were worth $177,000 at the end of the most []

After losing some value lately, a hammer chart pattern has been formed for Bellerophon Therapeutics (BLPH), indicating that the stock has found support. This, combined with an upward trend in earnings

Salarius Pharmaceuticals (NASDAQ:SLRX) and Bellerophon Therapeutics (NASDAQ:BLPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk. Analyst Ratings This is a summary of recent ratings for Salarius Pharmaceuticals and Bellerophon Therapeutics, []

WARREN, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the third quarter ended September 30, 2021.

WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing

Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest biopharma movers Wednesday.

Current & Former Penny Stocks To Watch Before July The post 8 Hot Biotech Penny Stocks For Your July 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.co

WARREN, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing tr

Dr. Amin Has Served as an Independent Director Since 2015 and Succeeds Jonathan Peacock Following Mr. Peacock's Retirement from the Company's Board Dr. Amin Has Served as an Independent Director Since

WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing tr

WARREN, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing

WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing t

WARREN, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing t

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilitie

WARREN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing t